Azurity Pharmaceuticals Recalls One Lot of Zenzedi (dextroamphetamine sulfate) 30mg Tablets

February 05, 2024

The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.

On Jan. 25, 2024, Azurity Pharmaceuticals announced the recall of one lot of the stimulant medication Zenzedi^® (dextroamphetamine sulfate tablets) 30mg to the consumer level after one bottle was found to contain the antihistamine carbinoxamine maleate. Zenzedi is approved for treating attention deficit hyperactivity disorder (ADHD) and narcolepsy. Patients who take carbinoxamine instead of Zenzedi could experience undertreatment of their disease symptoms. In addition, adverse effects from taking the antihistamine carbinoxamine maleate can include drowsiness and central nervous system depression. The FDA notice is here.

Last updated: February 05, 2024

The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.